

# Final Agenda

# 28<sup>th</sup> meeting of the Committee for Socio-economic Analysis

# 8-11 September 2015

ECHA Conference Centre (Annankatu 18, Helsinki)

8 September: starts at 14:00 11 September: ends at 13:30

#### Item 1 - Welcome and Apologies

## Item 2 - Adoption of the Agenda

SEAC/A/28/2015 For adoption

#### Item 3 - Declarations of conflicts of interest to the Agenda

#### Item 4 - Report from other ECHA bodies and activities

a) Report on SEAC-27 action points, written procedures and other ECHA bodies

SEAC/28/2015/01 For information

- b) General SEAC procedures (closed session)
  - Admission of stakeholder organisations

SEAC/28/2015/02 (restricted)
For discussion and agreement

Co-opted members

SEAC/28/2015/03 (restricted)
For discussion and agreement

## **Item 5 - Restrictions**

#### 5.1 General restriction issues

 a) Framework for RAC and SEAC in checking conformity and developing opinions on restriction proposals

SEAC/28/2015/04 For discussion and agreement

#### **5.2 Restriction Annex XV dossiers**

- a) Opinion development
  - 1) Isopropylidenediphenol (Bisphenol A) revised draft opinion

For agreement

2) DecaBDE - draft final opinion

For adoption

3) Perfluorooctanoic acid (PFOA) - revised draft opinion

For agreement

4) Methanol – first draft opinion

For discussion

5) D4/D5 - first draft opinion

For discussion

## 5.3 Appointment of (co-)rapporteurs for restriction dossiers

For information

## **Item 6 - Authorisations**

#### 6.1 General authorisation issues

a) Continuing review of SEAC and RAC recommendations

For discussion

b) Report from Authorisation Task Force

For information

c) Working Procedure on opinion development

SEAC/28/2015/05

For discussion and agreement

d) Update on incoming/future applications for authorisation

For information

#### 6.2 Authorisation applications

- a) Outcome of the conformity check and presentation of key issues
  - 1. Six uses of chromium trioxide submitted by *LANXESS Deutschland GmbH on behalf of a group of companies* (**Chromium trioxide 1**):

Use 1: Formulation of mixtures

Use 2: Functional chrome plating

Use 3: Functional chrome plating with decorative character

<u>Use 4:</u> Surface treatment for applications in the aeronautics and aerospace industries, unrelated to Functional chrome plating or Functional plating with decorative character

<u>Use 5:</u> Surface treatment (except ETP) for applications in various industry sectors namely architectural, automotive, metal manufacturing and finishing, and general engineering Use 6: Passivation of tin-plated steel (ETP)

2. One use of sodium chromate submitted by *Dometic GMBH and Dometic Htgépgyártó és Kereskedelmi Zrt.* (**Sodium chromate 1**):

<u>Use 1:</u> The use of sodium chromate as an anticorrosion agent of the carbon steel cooling system in absorption refrigerators up to 0.75% by weight (Cr 6+) in the cooling solution.

3. One use of sodium dichromate submitted by *Boliden Mineral AB* (**Sodium dichromate 1**):

<u>Use 1:</u> The use of sodium dichromate in copper/lead separation in concentrators handling complex sulphide ores.

4. One use of 1,2-dichloroethane submitted by *Laboratoires Expanscience* (**EDC 1**):

<u>Use 1</u>: process and extracting solvent in fine chemical processes

#### For discussion/agreement

- b) Final opinions
  - 1. One use of trichloroethylene submitted by *DOW Deutschland Anlagengesellschaft mbH* (**Trichloroethylene 2a**):

<u>Use 1</u>: Use of Trichloroethylene in Industrial Parts Cleaning by Vapour Degreasing in Closed Systems where specific requirements (system of use-parameters) exist

2. One use of lead chromate submitted by *Etienne LACROIX* (**Lead chromate 1**):

<u>Use 1</u>: Industrial use of lead chromate in manufacture of pyrotechnical delay devices contained into ammunition for naval self-protection

For adoption

6.3 Appointment of (co-)rapporteurs for authorisation applications (closed session)

SEAC/28/2015/06 (restricted room document) For agreement

# Item 7 - AOB

- a) Update of the work plan
- b) SEA tool kit
- c) Information by the Commission on the benefits indicators study
- d) Information on NL project: Costs of ED related health effects

For information

# Item 8 - Action points and main conclusions of SEAC-28

Table with Conclusions and Action points from SEAC-28

For adoption